• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

    10/6/25 5:46:39 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    ARCUTIS BIOTHERAPEUTICS INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    03969K108

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03969K108


    1Names of Reporting Persons

    Jennison Associates LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    12,254,119.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,254,119.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,254,119.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ARCUTIS BIOTHERAPEUTICS INC
    (b)Address of issuer's principal executive offices:

    3027 Townsgate Road, Suite 300, Westlake Village, CA 91361
    Item 2. 
    (a)Name of person filing:

    Jennison Associates LLC
    (b)Address or principal business office or, if none, residence:

    55 East 52nd Street, New York, NY 10055
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    03969K108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    12254119
    (b)Percent of class:

    10.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    12254119

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    12254119

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Jennison Associates LLC
     
    Signature:Beata Markowicz
    Name/Title:Senior Vice President, Compliance
    Date:10/06/2025
    Get the next $ARQT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    7/25/2025$18.00Neutral
    Goldman
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    More analyst ratings

    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Edwards Larry Todd sold $90,263 worth of shares (4,504 units at $20.04), decreasing direct ownership by 2% to 179,324 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    10/6/25 3:15:24 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Watanabe Todd sold $884,649 worth of shares (45,000 units at $19.66), decreasing direct ownership by 5% to 846,440 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    10/3/25 5:02:42 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Welgus Howard G. exercised 9,538 shares at a strike of $1.68 and sold $189,227 worth of shares (10,000 units at $18.92), decreasing direct ownership by 0.46% to 99,744 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    10/3/25 5:01:57 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

    ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere on the body for any durationAbout 1.8 million children ages 2 to 5 with atopic dermatitis are topically treated in the U.S.Sixth FDA approval for ZORYVE in just over three yearsCommercial product expected to be available by the end of October 2025 WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that the U.S.

    10/6/25 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis' common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted

    10/3/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET. In addition to discussing third quarter 2025 financial results, the Investor Day will feature: An in-depth look into the Company's strategy for long-term, sustained growth for ZORYVE® (roflumilast)A detailed review of clinical development activities and advancements for new ZORYVE indicat

    9/29/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

    SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    10/6/25 5:46:39 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    10/1/25 5:35:34 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    8/21/25 5:27:10 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/6/25 8:44:37 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    5/23/25 4:04:50 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

    Goldman initiated coverage of Arcutis Biotherapeutics with a rating of Neutral and set a new price target of $18.00

    7/25/25 9:06:04 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

    12/30/24 7:23:09 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

    Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

    8/28/24 7:20:44 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

    Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

    9/27/23 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces Leadership Transition

    Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t

    5/24/23 5:00:03 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/13/24 4:30:25 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/6/24 4:00:53 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

    Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand growthZORYVE foam 0.3% received U.S. Food and Drug Administration (FDA) approval for the treatment of plaque psoriasis of the scalp and body in adults and adolescents 12 years of age and olderInitiated INTEGUMENT-INFANT study to evaluate the safety and efficacy of ZORYVE cream 0.05% in infants with atopic dermatitis ages 3 months to 24 monthsSubmitted Investigational New Drug Application (IND) for ARQ-234, a novel fusion protein for the potential treatment of patients with atopic dermatitis WESTLAKE VI

    8/6/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

    WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the presentation materials will be available on the "Events" section of the Company's website. An archived replay of the webcast will be available on the Arcutis investor website following

    7/23/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

    Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditionsAll three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expandOn April 3, 2025, the patent litigation against Padagis was

    5/6/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care